ClinicalTrials.gg
CompletedNCT01927861Updated Aug 10, 2020Results posted

Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome

A Phase 3 interventional study of somatropin in Genetic Disorder and Noonan Syndrome, sponsored by Novo Nordisk A/S. Completed at 27 sites in Japan. Open to participants aged 3 Years to 10 Years. Per ClinicalTrials.gov, last updated 2020-08-10.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
3 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S — none open to participants now, 2 under way, 2 of them phase 3. Genetic Diseases, Inborn · Novo Nordisk A/S.

Enrollment
8th of 15
51 · median 51
Started
2013
the only one that year
Phase 3
8 of 23
none open now
Registered
17th of 23
by date

Among the 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S, this one is the 8th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2013, is one of 8 in phase 3, and was the 17th registered.

Genetic Diseases, Inborn

584 studies on the registry are indexed under Genetic Diseases, Inborn; 158 are open to participants now.

Browse Genetic Diseases, Inborn studies →

Open to participants now

None of the 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S is open now. The open studies under Genetic Diseases, Inborn, anywhere →

Who these studies take

Of the 121 Genetic Diseases, Inborn studies recruiting now, 60 (50%) set no upper age limit and 46 (38%) stop at 75 or younger; 86 take children under 18; 28 take healthy volunteers.

This study: 3 Years to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S as a file.
02

Study summary

This trial is conducted in Asia. The aim of the trial is to investigate the long-term efficacy and safety of two doses of NN-220 (somatropin) in short stature due to Noonan syndrome.

03

Conditions studied

  • Genetic Disorder
  • Noonan Syndrome
04

Who can participate

Ages eligible
3 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese children with Noonan syndrome clinically diagnosed in one of the following ways: 1. Clinically diagnosed by at least two medical experts using van der Burgt score list, 2. Clinically diagnosed by one medical expert using van der Burgt score list and diagnosed by result of genetic testing for Noonan syndrome, 3. Clinically diagnosed by one medical expert using van der Burgt score list and diagnosed by the same medical expert based on the results of centralised evaluation of facial change using van der Burgt score list
  • Height SDS (standard deviation score): -2 SDS or below (according to the Japanese reference data)
  • Age: boys 3 to below 11 years, girls 3 to below 10 years
  • Height records must be available within the period between 40 and 64 weeks prior to Visit 1 (screening)
  • Prepubertal children (definition for girls breast and pubes of Tanner stage is I, and none of menses, and for boys testicular volume below 4 mL, and pubes and penis of Tanner stage is I)

Exclusion criteria

Exclusion Criteria:

  • Children with known or suspected against human growth hormone (hGH) or related products (including any components of the trial products)
  • Children with diabetic type diagnosed with the Japanese Diabetes Society Classification
  • Children with history or presence of active
  • Children who have received GH (growth hormone) treatment
  • Children who have received systemic administration of the following medications within two years prior to Visit 1 (screening): Thyroid hormone (except replacement therapy), antithyroid hormone, androgen, oestrogen, progesterone, anabolic steroid, adrenocortical treatment period for at least 13 weeks), derivative of gonadotropin releasing hormone and somatomedin C (IGF-I)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    0.033 mg/kg/day

    Drug: somatropin

  • Experimental
    0.066 mg/kg/day

    Drug: somatropin

Interventions

  • Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Height SDS (Japanese National Reference Data)

    Height SDS was calculated using the formula: SDS = (height - mean)/SD, where height was the height variable measured, mean and SD of height by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height and negative SDS indicated lesser height than the mean of the reference population. The change from baseline (week 0) in the height SDS after 104 weeks of treatment was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline height SDS as a covariate. Positive value in change from baseline indicated that SDS was better than baseline SDS. Missing values were imputed using the last observation carried forward (LOCF) method.

    Time frame: Baseline, week 104

Secondary outcomes

  1. Height Velocity SDS

    Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 52) and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using the formula: SDS = (height velocity - mean)/SD, where height velocity was the height velocity variable measured, mean and SD of height velocity by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height velocity and negative SDS indicated lesser height velocity than the mean of the reference population.

    Time frame: Baseline to week 52

  2. Height Velocity SDS

    Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 104) and height at week 52 divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using the formula: SDS = (height velocity - mean)/SD, where height velocity was the height velocity variable measured, mean and SD of height velocity by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height velocity and negative SDS indicated lesser height velocity than the mean of the reference population.

    Time frame: Week 52 to week 104

  3. Height Velocity

    Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 52) and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days.

    Time frame: Baseline to week 52

  4. Height Velocity

    Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 104) and height at week 52 divided by time between those measurement time points and multiplied by 365 days.

    Time frame: Week 52 to week 104

  5. Incidence of Treatment Emergent Adverse Events

    A treatment emergent adverse event (TEAE; for the pivotal phase) was defined as an event that had onset date on or after the date of visit 2 (week 0; start of treatment) and no later than the date of visit 12 (104 weeks; end of pivotal phase). For withdrawal participants (if any), an adverse event with onset date no later than 7 days after the last day of NN-220 treatment was included.

    Time frame: During 104 weeks of treatment

  6. Change in IGF-I (Insulin-like Growth Factor-I)

    Change from baseline (within 4 weeks prior to week 0) in IGF-I was evaluated after 104 weeks of treatment. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 104

  7. Change in HbA1c (Glycosylated Haemoglobin)

    Change from baseline (within 4 weeks prior to week 0) in HbA1c was evaluated after 104 weeks of treatment.

    Time frame: Baseline, week 104

  8. Change in Clinical Laboratory Tests (Haematology: Erythrocytes)

    Change from baseline (within 4 weeks prior to week 0) in haematological parameter - erythrocytes. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 104

  9. Change in Clinical Laboratory Tests (Haematology: Leukocytes and Thrombocytes)

    Change from baseline (within 4 weeks prior to week 0) in haematological parameter - leukocytes and thrombocytes. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 104

  10. Change in Clinical Laboratory Tests (Haematology: Haemoglobin)

    Change from baseline (within 4 weeks prior to week 0) in haematological parameter - haemoglobin. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 104

  11. Change in Clinical Laboratory Tests (Haematology: Haematocrit)

    Change from baseline (within 4 weeks prior to week 0) in haematological parameter - haematocrit. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 104

  12. Change in Clinical Laboratory Tests (Haematology: Neutrophils)

    Change from baseline (within 4 weeks prior to week 0) in haematological parameter - neutrophils. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 104

  13. Change in Clinical Laboratory Tests (Haematology: Lymphocytes)

    Change from baseline (within 4 weeks prior to week 0) in haematological parameter - lymphocytes. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 104

  14. Change in Clinical Laboratory Tests (Haematology: Monocytes)

    Change from baseline (within 4 weeks prior to week 0) in haematological parameter - monocytes. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 104

  15. Change in Clinical Laboratory Tests (Haematology: Eosinophils)

    Change from baseline (within 4 weeks prior to week 0) in haematological parameter - eosinophils. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 104

  16. Change in Clinical Laboratory Tests (Haematology: Basophils)

    Change from baseline (within 4 weeks prior to week 0) in haematological parameter - basophils. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 104

  17. Change in Clinical Laboratory Tests (Lipids: Total Cholesterol, LDL Cholesterol and HDL Cholesterol)

    Change from baseline (within 4 weeks prior to week 0) in lipids: total cholesterol, LDL (low-density lipoprotein) cholesterol and HDL (high-density lipoprotein) cholesterol. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 104

  18. Change in Clinical Laboratory Tests (Biochemistry: AST, ALT, r-GTP and Alkaline Phosphatase)

    Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (r-GTP) and alkaline phosphatase. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 104

  19. Change in Clinical Laboratory Tests (Biochemistry: Total Protein)

    Change from baseline (within 4 weeks prior to week 0) in biochemical parameter - total protein. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 104

  20. Change in Clinical Laboratory Tests (Biochemistry: Blood Urea Nitrogen, Sodium, Potassium, Chloride, Total Calcium and Phosphorus)

    Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - blood urea nitrogen, sodium, potassium, chloride, total calcium and phosphorus. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 104

  21. Change in Clinical Laboratory Tests (Biochemistry: Creatinine)

    Change from baseline (within 4 weeks prior to week 0) in biochemical parameter - creatinine. Missing values were imputed using the LOCF method.

    Time frame: Baseline, Week 104

  22. Change in Glucose Tolerance (AUC of Glucose) Based on the OGTT

    AUC (area under the curve) of glucose was calculated by the trapezoidal method. Change from baseline (within 4 weeks prior to week 0) in glucose tolerance (AUC of glucose: 30, 60, 90 and 120 min after oral glucose load) at week 104 was evaluated based on the oral glucose tolerance test (OGTT). Change from baseline results are presented as 'ratio to baseline'.

    Time frame: Baseline, week 104

  23. Change in Glucose Tolerance (AUC of Insulin) Based on the OGTT

    AUC of insulin was calculated by the trapezoidal method. Change from baseline (within 4 weeks prior to week 0) in glucose tolerance (AUC of insulin: 30, 60, 90 and 120 min after oral glucose load) at week 104 was evaluated based on the OGTT. Change from baseline results are presented as 'ratio to baseline'.

    Time frame: Baseline, week 104

  24. Change in Bone Age

    X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the radius, ulna and short bones (RUS) score method of Tanner-Whitehouse II (TW2). Change from baseline (week 0) in bone age.

    Time frame: Baseline, week 104

  25. Change in Bone Age/Chronological Age

    X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Change from baseline (week 0) in bone age/chronological age.

    Time frame: Baseline, week 104

  26. Yearly Change in Bone Age/Change in Chronological Age

    X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Yearly change from baseline (week 0) in bone age/change in chronological age was presented.

    Time frame: Baseline, week 52

  27. Yearly Change in Bone Age/Change in Chronological Age

    X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Yearly change from week 52 in bone age/change in chronological age was presented.

    Time frame: Week 52, week 104

  28. Change in Vital Signs (Diastolic Blood Pressure and Systolic Blood Pressure)

    Systolic and diastolic blood pressure were measured after a 5-minute rest in sitting position. Change from baseline (week 0) in systolic blood pressure and diastolic blood pressure.

    Time frame: Baseline, week 104

  29. Change in Vital Signs (Pulse)

    Pulse was measured after a 5-minute rest in sitting position. Change from baseline (week 0) in pulse.

    Time frame: Baseline, week 104

  30. Change in Urinalysis (Protein, Glucose and Occult Blood)

    The urinalysis was the measurements of protein, glucose, and occult blood at baseline (within 4 weeks prior to week 0) and week 104 and categorised as negative, trace, 1+, 2+ and 3+. Missing values were imputed using the LOCF method. Number of participants in each category at baseline and week 104 are presented.

    Time frame: Baseline, week 104

  31. Change in Blood Coagulation Test (Prothrombin Time and APTT)

    Change from baseline (within 4 weeks prior to week 0) in blood coagulation test parameters: Prothrombin time and APTT (activated partial thromboplastin time). Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 104

  32. Change in ECG

    The ECG was recorded after a 3-minute rest in supine position at baseline (within 4 weeks prior to week 0) and week 104 and categorised as normal, abnormal NCS (not clinically significant) or abnormal CS (clinically significant). Number of participants in each ECG category at baseline and week 104 are presented. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 104

  33. Change in Height SDS (Japanese National Reference Data)

    Height SDS was calculated using the formula: SDS = (height - mean)/SD, where height was the height variable measured, mean and SD of height by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height and negative SDS indicated lesser height than the mean of the reference population. The change from baseline (week 0) in the height SDS after 208 weeks of treatment was analysed. Positive value in change from baseline indicated that SDS was better than baseline SDS. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  34. Change in Height SDS (Noonan Syndrome Reference Data in Japanese)

    Height SDS was calculated using the formula: Z=\[(value/M)\^L-1\]/(S\*L); where L, M and S are skewness (L), median (M) and coefficient of variation (S) of Japanese Noonan syndrome' height provided for each sex and age. For each participant, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The scores were centered around zero. Positive SDS indicated greater height and negative SDS indicated lesser height than the mean of the reference population. The change from baseline (week 0) in the height SDS after 208 weeks of treatment was analysed. Positive value in change from baseline indicated that SDS was better than baseline SDS. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  35. Height Velocity

    Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 156) and height at week 104 divided by time between those measurement time points and multiplied by 365 days. Missing values were imputed using the LOCF method.

    Time frame: Week 104 to week 156

  36. Height Velocity

    Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 208) and height at week 156 divided by time between those measurement time points and multiplied by 365 days. Missing values were imputed using the LOCF method.

    Time frame: Week 156 to week 208

  37. Height Velocity SDS

    Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 156) and height at week 104 divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using the formula: SDS = (height velocity - mean)/SD, where height velocity was the height velocity variable measured, mean and SD of height velocity by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height velocity and negative SDS indicated lesser height velocity than the mean of the reference population.

    Time frame: Week 104 to week 156

  38. Height Velocity SDS

    Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 208) and height at week 156 divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using the formula: SDS = (height velocity - mean)/SD, where height velocity was the height velocity variable measured, mean and SD of height velocity by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height velocity and negative SDS indicated lesser height velocity than the mean of the reference population.

    Time frame: Week 156 to week 208

  39. Incidence of Treatment Emergent AEs

    A treatment emergent AE (TEAE) was defined as an event that had onset date on or after the date of visit 2 (week 0; start of treatment) and no later than 7 days after the last day of NN-220 treatment.

    Time frame: Week 0 to week 234 (208 weeks treatment period + 26 weeks extended treatment period) + 7 days (follow-up period)

  40. Change in IGF-I

    Change from baseline (within 4 weeks prior to week 0) in IGF-I was evaluated after 208 weeks of treatment. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  41. Change in HbA1c

    Change from baseline (within 4 weeks prior to week 0) in HbA1c was evaluated after 208 weeks of treatment.

    Time frame: Baseline, week 208

  42. Change in Clinical Laboratory Tests (Haematology: Erythrocytes)

    Change from baseline (within 4 weeks prior to week 0) in haematological parameter - erythrocytes. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  43. Change in Clinical Laboratory Tests (Haematology: Leukocytes and Thrombocytes)

    Change from baseline (within 4 weeks prior to week 0) in haematological parameter - leukocytes and thrombocytes. Missing values were imputed using the LOCF method.

    Time frame: Baseline, Week 208

  44. Change in Clinical Laboratory Tests (Haematology: Haemoglobin)

    Change from baseline (within 4 weeks prior to week 0) in haematological parameter - haemoglobin. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  45. Change in Clinical Laboratory Tests (Haematology: Haematocrit)

    Change from baseline (within 4 weeks prior to week 0) in haematological parameter - haematocrit. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  46. Change in Clinical Laboratory Tests (Haematology: Neutrophils)

    Change from baseline (within 4 weeks prior to week 0) in haematological parameter - neutrophils. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  47. Change in Clinical Laboratory Tests (Haematology: Lymphocytes)

    Change from baseline (within 4 weeks prior to week 0) in haematological parameter - lymphocytes. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  48. Change in Clinical Laboratory Tests (Haematology: Monocytes)

    Change from baseline (within 4 weeks prior to week 0) in haematological parameter - monocytes. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  49. Change in Clinical Laboratory Tests (Haematology: Eosinophils)

    Change from baseline (within 4 weeks prior to week 0) in haematological parameter - eosinophils. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  50. Change in Clinical Laboratory Tests (Haematology: Basophils)

    Change from baseline (within 4 weeks prior to week 0) in haematological parameter - basophils. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  51. Change in Clinical Laboratory Tests (Lipids: Total Cholesterol, LDL Cholesterol and HDL Cholesterol)

    Change from baseline (within 4 weeks prior to week 0) in lipids: total cholesterol, LDL cholesterol and HDL cholesterol. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  52. Change in Clinical Laboratory Tests (Biochemistry: AST, ALT, r-GTP and Alkaline Phosphatase)

    Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - AST, ALT, r-GTP and alkaline phosphatase. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  53. Change in Clinical Laboratory Tests (Biochemistry: Total Protein)

    Change from baseline (within 4 weeks prior to week 0) in biochemical parameter - total protein. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  54. Change in Clinical Laboratory Tests (Biochemistry: Blood Urea Nitrogen, Sodium, Potassium, Chloride, Total Calcium and Phosphorus)

    Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - blood urea nitrogen, sodium, potassium, chloride, total calcium and phosphorus. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  55. Change in Clinical Laboratory Tests (Biochemistry: Creatinine)

    Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - creatinine. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  56. Change in Glucose Tolerance (AUC of Glucose) Based on the OGTT

    AUC of glucose was calculated by the trapezoidal method. Change from baseline (within 4 weeks prior to week 0) in glucose tolerance (AUC of glucose: 30, 60, 90 and 120 min after oral glucose load) at week 208 was evaluated based on the OGTT. Change from baseline results are presented as 'ratio to baseline'.

    Time frame: Baseline, week 208

  57. Change in Glucose Tolerance (AUC of Insulin) Based on the OGTT

    AUC of insulin was calculated by the trapezoidal method. Change from baseline (within 4 weeks prior to week 0) in glucose tolerance (AUC of insulin: 30, 60, 90 and 120 min after oral glucose load) at week 208 was evaluated based on the OGTT. Change from baseline results are presented as 'ratio to baseline'.

    Time frame: Baseline, week 208

  58. Change in Bone Age

    X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Change from baseline (week 0) in bone age.

    Time frame: Baseline, week 208

  59. Change in Bone Age/Chronological Age

    X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Change from baseline (week 0) in bone age/chronological age.

    Time frame: Baseline, week 208

  60. Yearly Change in Bone Age/Change in Chronological Age

    X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Yearly change from week 104 in bone age/change in chronological age was presented.

    Time frame: Week 104, week 156

  61. Yearly Change in Bone Age/Change in Chronological Age

    X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Yearly change from week 156 in bone age/change in chronological age was presented.

    Time frame: Week 156, week 208

  62. Change in Vital Signs (Diastolic Blood Pressure and Systolic Blood Pressure)

    Systolic and diastolic blood pressure were measured after a 5-minute rest in sitting position. Change from baseline (week 0) in systolic blood pressure and diastolic blood pressure. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  63. Change in Vital Signs (Pulse)

    Pulse was measured after a 5-minute rest in sitting position. Change from baseline (week 0) in pulse. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  64. Change in Urinalysis (Protein, Glucose and Occult Blood)

    The urinalysis was the measurements of protein, glucose, and occult blood at baseline (within 4 weeks prior to week 0) and week 208 and categorised as negative, trace, 1+, 2+ and 3+. Number of participants in each category at baseline and week 208 are presented. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  65. Change in Blood Coagulation Test (Prothrombin Time and APTT)

    Change from baseline (within 4 weeks prior to week 0) in blood coagulation test parameters: prothrombin time and APTT. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

  66. Change in ECG

    The ECG was recorded after a 3-minute rest in supine position at baseline (within 4 weeks prior to week 0) and week 208 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline and week 208 are presented. Missing values were imputed using the LOCF method.

    Time frame: Baseline, week 208

07

Results

Posted Oct 14, 2019

Participant flow

The trial was conducted at 26 sites in Japan.

Pivotal Phase (104 Weeks)
Participant flow — Pivotal Phase (104 Weeks)
MilestoneNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Started2526
Completed2526
Not completed00
Extension Phase (104 Weeks)
Participant flow — Extension Phase (104 Weeks)
MilestoneNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Started2526
Completed2523
Not completed03
Withdrew: Adverse event02
Withdrew: Unclassified01
Extended Treatment Phase (26 Weeks)
Participant flow — Extended Treatment Phase (26 Weeks)
MilestoneNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Started1514
Completed1514
Not completed00

Outcome measures

PrimaryChange in Height SDS (Japanese National Reference Data)

Height SDS was calculated using the formula: SDS = (height - mean)/SD, where height was the height variable measured, mean and SD of height by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height and negative SDS indicated lesser height than the mean of the reference population. The change from baseline (week 0) in the height SDS after 104 weeks of treatment was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline height SDS as a covariate. Positive value in change from baseline indicated that SDS was better than baseline SDS. Missing values were imputed using the last observation carried forward (LOCF) method.

Time frame:
Baseline, week 104
Reported as:
Least squares mean · Standard deviation score
Change in Height SDS (Japanese National Reference Data)
Standard deviation scoreNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Height SDS (Japanese National Reference Data)0.84 ± 0.091.47 ± 0.09
Statistical analysis
  • NN-220 0.033 mg/kg/Day vs NN-220 0.066 mg/kg/Day · ANCOVA · p = < 0.0001 · Treatment difference: 0.63 · 95% CI 0.38 to 0.88
SecondaryHeight Velocity SDS

Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 52) and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using the formula: SDS = (height velocity - mean)/SD, where height velocity was the height velocity variable measured, mean and SD of height velocity by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height velocity and negative SDS indicated lesser height velocity than the mean of the reference population.

Time frame:
Baseline to week 52
Reported as:
Mean · Standard deviation score
Height Velocity SDS
Standard deviation scoreNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Height Velocity SDS2.80 ± 1.135.01 ± 1.92
SecondaryHeight Velocity SDS

Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 104) and height at week 52 divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using the formula: SDS = (height velocity - mean)/SD, where height velocity was the height velocity variable measured, mean and SD of height velocity by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height velocity and negative SDS indicated lesser height velocity than the mean of the reference population.

Time frame:
Week 52 to week 104
Reported as:
Mean · Standard deviation score
Height Velocity SDS
Standard deviation scoreNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Height Velocity SDS0.58 ± 1.592.65 ± 1.76
SecondaryHeight Velocity

Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 52) and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days.

Time frame:
Baseline to week 52
Reported as:
Mean · Centimeters per year (cm/year)
Height Velocity
Centimeters per year (cm/year)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Height Velocity7.88 ± 0.879.90 ± 1.49
SecondaryHeight Velocity

Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 104) and height at week 52 divided by time between those measurement time points and multiplied by 365 days.

Time frame:
Week 52 to week 104
Reported as:
Mean · cm/year
Height Velocity
cm/yearNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Height Velocity6.20 ± 0.957.99 ± 1.20
SecondaryIncidence of Treatment Emergent Adverse Events

A treatment emergent adverse event (TEAE; for the pivotal phase) was defined as an event that had onset date on or after the date of visit 2 (week 0; start of treatment) and no later than the date of visit 12 (104 weeks; end of pivotal phase). For withdrawal participants (if any), an adverse event with onset date no later than 7 days after the last day of NN-220 treatment was included.

Time frame:
During 104 weeks of treatment
Reported as:
Number · Events
Incidence of Treatment Emergent Adverse Events
EventsNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Incidence of Treatment Emergent Adverse Events265306
SecondaryChange in IGF-I (Insulin-like Growth Factor-I)

Change from baseline (within 4 weeks prior to week 0) in IGF-I was evaluated after 104 weeks of treatment. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 104
Reported as:
Mean · Nanograms per milliliter (ng/mL)
Change in IGF-I (Insulin-like Growth Factor-I)
Nanograms per milliliter (ng/mL)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in IGF-I (Insulin-like Growth Factor-I)90.4 ± 65.5159.1 ± 88.0
SecondaryChange in HbA1c (Glycosylated Haemoglobin)

Change from baseline (within 4 weeks prior to week 0) in HbA1c was evaluated after 104 weeks of treatment.

Time frame:
Baseline, week 104
Reported as:
Mean · Percentage of HbA1c
Change in HbA1c (Glycosylated Haemoglobin)
Percentage of HbA1cNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in HbA1c (Glycosylated Haemoglobin)0.14 ± 0.180.13 ± 0.20
SecondaryChange in Clinical Laboratory Tests (Haematology: Erythrocytes)

Change from baseline (within 4 weeks prior to week 0) in haematological parameter - erythrocytes. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 104
Reported as:
Mean · 10^12 cells per liter (10^12 cells/L)
Change in Clinical Laboratory Tests (Haematology: Erythrocytes)
10^12 cells per liter (10^12 cells/L)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Haematology: Erythrocytes)0.106 ± 0.3000.165 ± 0.234
SecondaryChange in Clinical Laboratory Tests (Haematology: Leukocytes and Thrombocytes)

Change from baseline (within 4 weeks prior to week 0) in haematological parameter - leukocytes and thrombocytes. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 104
Reported as:
Mean · 10^9 cells per liter (10^9 cells/L)
Change in Clinical Laboratory Tests (Haematology: Leukocytes and Thrombocytes)
10^9 cells per liter (10^9 cells/L)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Leukocytes-0.69 ± 2.28-1.01 ± 1.77
Thrombocytes-6.9 ± 60.2-29.0 ± 63.2
SecondaryChange in Clinical Laboratory Tests (Haematology: Haemoglobin)

Change from baseline (within 4 weeks prior to week 0) in haematological parameter - haemoglobin. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 104
Reported as:
Mean · Millimoles per liter (mmol/L)
Change in Clinical Laboratory Tests (Haematology: Haemoglobin)
Millimoles per liter (mmol/L)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Haematology: Haemoglobin)0.26 ± 0.460.32 ± 0.55
SecondaryChange in Clinical Laboratory Tests (Haematology: Haematocrit)

Change from baseline (within 4 weeks prior to week 0) in haematological parameter - haematocrit. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 104
Reported as:
Mean · Percentage of red blood cells
Change in Clinical Laboratory Tests (Haematology: Haematocrit)
Percentage of red blood cellsNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Haematology: Haematocrit)0.85 ± 2.110.94 ± 1.93
SecondaryChange in Clinical Laboratory Tests (Haematology: Neutrophils)

Change from baseline (within 4 weeks prior to week 0) in haematological parameter - neutrophils. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 104
Reported as:
Mean · Percentage of neutrophils
Change in Clinical Laboratory Tests (Haematology: Neutrophils)
Percentage of neutrophilsNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Haematology: Neutrophils)-4.28 ± 11.444.50 ± 9.01
SecondaryChange in Clinical Laboratory Tests (Haematology: Lymphocytes)

Change from baseline (within 4 weeks prior to week 0) in haematological parameter - lymphocytes. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 104
Reported as:
Mean · Percentage of lymphocytes
Change in Clinical Laboratory Tests (Haematology: Lymphocytes)
Percentage of lymphocytesNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Haematology: Lymphocytes)2.80 ± 9.07-4.73 ± 8.73
SecondaryChange in Clinical Laboratory Tests (Haematology: Monocytes)

Change from baseline (within 4 weeks prior to week 0) in haematological parameter - monocytes. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 104
Reported as:
Mean · Percentage of monocytes
Change in Clinical Laboratory Tests (Haematology: Monocytes)
Percentage of monocytesNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Haematology: Monocytes)0.38 ± 1.410.39 ± 1.35
SecondaryChange in Clinical Laboratory Tests (Haematology: Eosinophils)

Change from baseline (within 4 weeks prior to week 0) in haematological parameter - eosinophils. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 104
Reported as:
Mean · Percentage of eosinophils
Change in Clinical Laboratory Tests (Haematology: Eosinophils)
Percentage of eosinophilsNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Haematology: Eosinophils)0.99 ± 2.95-0.05 ± 1.33
SecondaryChange in Clinical Laboratory Tests (Haematology: Basophils)

Change from baseline (within 4 weeks prior to week 0) in haematological parameter - basophils. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 104
Reported as:
Mean · Percentage of basophils
Change in Clinical Laboratory Tests (Haematology: Basophils)
Percentage of basophilsNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Haematology: Basophils)0.10 ± 0.36-0.07 ± 0.27
SecondaryChange in Clinical Laboratory Tests (Lipids: Total Cholesterol, LDL Cholesterol and HDL Cholesterol)

Change from baseline (within 4 weeks prior to week 0) in lipids: total cholesterol, LDL (low-density lipoprotein) cholesterol and HDL (high-density lipoprotein) cholesterol. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 104
Reported as:
Mean · mmol/L
Change in Clinical Laboratory Tests (Lipids: Total Cholesterol, LDL Cholesterol and HDL Cholesterol)
mmol/LNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Total cholesterol0.073 ± 0.655-0.110 ± 0.371
LDL cholesterol0.040 ± 0.521-0.120 ± 0.323
HDL cholesterol-0.020 ± 0.212-0.034 ± 0.210
SecondaryChange in Clinical Laboratory Tests (Biochemistry: AST, ALT, r-GTP and Alkaline Phosphatase)

Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (r-GTP) and alkaline phosphatase. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 104
Reported as:
Mean · Units per liter (U/L)
Change in Clinical Laboratory Tests (Biochemistry: AST, ALT, r-GTP and Alkaline Phosphatase)
Units per liter (U/L)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
AST-3.6 ± 2.9-6.0 ± 4.3
ALT-1.04 ± 3.10-1.73 ± 4.20
r-GTP0.4 ± 1.6-3.7 ± 19.4
Alkaline phosphatase73.8 ± 76.3124.3 ± 124.0
SecondaryChange in Clinical Laboratory Tests (Biochemistry: Total Protein)

Change from baseline (within 4 weeks prior to week 0) in biochemical parameter - total protein. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 104
Reported as:
Mean · Grams per deciliter (g/dL)
Change in Clinical Laboratory Tests (Biochemistry: Total Protein)
Grams per deciliter (g/dL)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Biochemistry: Total Protein)0.02 ± 0.38-0.05 ± 0.27
SecondaryChange in Clinical Laboratory Tests (Biochemistry: Blood Urea Nitrogen, Sodium, Potassium, Chloride, Total Calcium and Phosphorus)

Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - blood urea nitrogen, sodium, potassium, chloride, total calcium and phosphorus. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 104
Reported as:
Mean · mmol/L
Change in Clinical Laboratory Tests (Biochemistry: Blood Urea Nitrogen, Sodium, Potassium, Chloride, Total Calcium and Phosphorus)
mmol/LNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Blood urea nitrogen-0.17 ± 0.38-0.21 ± 0.44
Sodium-0.3 ± 2.4-0.2 ± 2.6
Potassium-0.03 ± 0.32-0.15 ± 0.41
Chloride-0.8 ± 2.3-1.3 ± 1.9
Total calcium0.00 ± 0.080.01 ± 0.07
Phosphorus0.124 ± 0.1250.129 ± 0.141
SecondaryChange in Clinical Laboratory Tests (Biochemistry: Creatinine)

Change from baseline (within 4 weeks prior to week 0) in biochemical parameter - creatinine. Missing values were imputed using the LOCF method.

Time frame:
Baseline, Week 104
Reported as:
Mean · Micromoles per liter (umol/L)
Change in Clinical Laboratory Tests (Biochemistry: Creatinine)
Micromoles per liter (umol/L)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Biochemistry: Creatinine)1.8 ± 3.52.5 ± 3.4
SecondaryChange in Glucose Tolerance (AUC of Glucose) Based on the OGTT

AUC (area under the curve) of glucose was calculated by the trapezoidal method. Change from baseline (within 4 weeks prior to week 0) in glucose tolerance (AUC of glucose: 30, 60, 90 and 120 min after oral glucose load) at week 104 was evaluated based on the oral glucose tolerance test (OGTT). Change from baseline results are presented as 'ratio to baseline'.

Time frame:
Baseline, week 104
Reported as:
Geometric mean · Ratio of AUC
Change in Glucose Tolerance (AUC of Glucose) Based on the OGTT
Ratio of AUCNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Glucose Tolerance (AUC of Glucose) Based on the OGTT0.98 ± 12.191.04 ± 17.75
SecondaryChange in Glucose Tolerance (AUC of Insulin) Based on the OGTT

AUC of insulin was calculated by the trapezoidal method. Change from baseline (within 4 weeks prior to week 0) in glucose tolerance (AUC of insulin: 30, 60, 90 and 120 min after oral glucose load) at week 104 was evaluated based on the OGTT. Change from baseline results are presented as 'ratio to baseline'.

Time frame:
Baseline, week 104
Reported as:
Geometric mean · Ratio of AUC
Change in Glucose Tolerance (AUC of Insulin) Based on the OGTT
Ratio of AUCNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Glucose Tolerance (AUC of Insulin) Based on the OGTT1.25 ± 45.081.72 ± 85.78
SecondaryChange in Bone Age

X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the radius, ulna and short bones (RUS) score method of Tanner-Whitehouse II (TW2). Change from baseline (week 0) in bone age.

Time frame:
Baseline, week 104
Reported as:
Mean · Years
Change in Bone Age
YearsNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Bone Age2.07 ± 0.802.63 ± 0.94
SecondaryChange in Bone Age/Chronological Age

X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Change from baseline (week 0) in bone age/chronological age.

Time frame:
Baseline, week 104
Reported as:
Mean · Ratio (bone age/chronological age)
Change in Bone Age/Chronological Age
Ratio (bone age/chronological age)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Bone Age/Chronological Age0.047 ± 0.1270.133 ± 0.127
SecondaryYearly Change in Bone Age/Change in Chronological Age

X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Yearly change from baseline (week 0) in bone age/change in chronological age was presented.

Time frame:
Baseline, week 52
Reported as:
Mean · Ratio (bone age/chronological age)
Yearly Change in Bone Age/Change in Chronological Age
Ratio (bone age/chronological age)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Yearly Change in Bone Age/Change in Chronological Age0.93 ± 0.661.28 ± 0.70
SecondaryYearly Change in Bone Age/Change in Chronological Age

X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Yearly change from week 52 in bone age/change in chronological age was presented.

Time frame:
Week 52, week 104
Reported as:
Mean · Ratio (bone age/chronological age)
Yearly Change in Bone Age/Change in Chronological Age
Ratio (bone age/chronological age)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Yearly Change in Bone Age/Change in Chronological Age1.15 ± 0.571.38 ± 0.91
SecondaryChange in Vital Signs (Diastolic Blood Pressure and Systolic Blood Pressure)

Systolic and diastolic blood pressure were measured after a 5-minute rest in sitting position. Change from baseline (week 0) in systolic blood pressure and diastolic blood pressure.

Time frame:
Baseline, week 104
Reported as:
Mean · Millimeters of mercury (mmHg)
Change in Vital Signs (Diastolic Blood Pressure and Systolic Blood Pressure)
Millimeters of mercury (mmHg)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Diastolic blood pressure2.3 ± 13.26.3 ± 15.8
Systolic blood pressure5.5 ± 11.94.1 ± 12.1
SecondaryChange in Vital Signs (Pulse)

Pulse was measured after a 5-minute rest in sitting position. Change from baseline (week 0) in pulse.

Time frame:
Baseline, week 104
Reported as:
Mean · Beats per minute (beats/min)
Change in Vital Signs (Pulse)
Beats per minute (beats/min)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Vital Signs (Pulse)-9.5 ± 15.71.8 ± 21.9
SecondaryChange in Urinalysis (Protein, Glucose and Occult Blood)

The urinalysis was the measurements of protein, glucose, and occult blood at baseline (within 4 weeks prior to week 0) and week 104 and categorised as negative, trace, 1+, 2+ and 3+. Missing values were imputed using the LOCF method. Number of participants in each category at baseline and week 104 are presented.

Time frame:
Baseline, week 104
Reported as:
Count of participants · Participants
Change in Urinalysis (Protein, Glucose and Occult Blood)
ParticipantsNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Protein: Negative (Baseline)2322
Protein: Trace (Baseline)24
Protein: 1+ (Baseline)00
Protein: 2+ (Baseline)00
Protein: 3+ (Baseline)00
Protein: Negative (Week 104)1816
Protein: Trace (Week 104)78
Protein: 1+ (Week 104)02
Protein: 2+ (Week 104)00
Protein: 3+ (Week 104)00
Glucose: Negative (Baseline)2526
Glucose: Trace (Baseline)00
Glucose: 1+ (Baseline)00
Glucose: 2+ (Baseline)00
Glucose: 3+ (Baseline)00
Glucose: Negative (Week 104)2526
Glucose: Trace (Week 104)00
Glucose: 1+ (Week 104)00
Glucose: 2+ (Week 104)00
Glucose: 3+ (Week 104)00
Occult blood: Negative (Baseline)2425
Occult blood: Trace (Baseline)11
Occult blood: 1+ (Baseline)00
Occult blood: 2+ (Baseline)00
Occult blood: 3+ (Baseline)00
Occult blood: Negative (Week 104)2520
Occult blood: Trace (Week 104)05
Occult blood: 1+ (Week 104)00
Occult blood: 2+ (Week 104)01
Occult blood: 3+ (Week 104)00
SecondaryChange in Blood Coagulation Test (Prothrombin Time and APTT)

Change from baseline (within 4 weeks prior to week 0) in blood coagulation test parameters: Prothrombin time and APTT (activated partial thromboplastin time). Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 104
Reported as:
Median · Second (sec)
Change in Blood Coagulation Test (Prothrombin Time and APTT)
Second (sec)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Prothrombin time0.50 (-1.8 to 2.3)0.80 (-0.6 to 2.3)
APTT0.60 (-4.0 to 4.7)0.25 (-9.1 to 5.6)
SecondaryChange in ECG

The ECG was recorded after a 3-minute rest in supine position at baseline (within 4 weeks prior to week 0) and week 104 and categorised as normal, abnormal NCS (not clinically significant) or abnormal CS (clinically significant). Number of participants in each ECG category at baseline and week 104 are presented. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 104
Reported as:
Count of participants · Participants
Change in ECG
ParticipantsNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Normal (Baseline)1514
Abnormal NCS (Baseline)1012
Abnormal CS (Baseline)00
Normal (Week 104)1613
Abnormal NCS (Week 104)913
Abnormal CS (Week 104)00
SecondaryChange in Height SDS (Japanese National Reference Data)

Height SDS was calculated using the formula: SDS = (height - mean)/SD, where height was the height variable measured, mean and SD of height by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height and negative SDS indicated lesser height than the mean of the reference population. The change from baseline (week 0) in the height SDS after 208 weeks of treatment was analysed. Positive value in change from baseline indicated that SDS was better than baseline SDS. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Mean · Standard deviation score
Change in Height SDS (Japanese National Reference Data)
Standard deviation scoreNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Height SDS (Japanese National Reference Data)0.85 ± 0.601.84 ± 0.70
SecondaryChange in Height SDS (Noonan Syndrome Reference Data in Japanese)

Height SDS was calculated using the formula: Z=\[(value/M)\^L-1\]/(S\*L); where L, M and S are skewness (L), median (M) and coefficient of variation (S) of Japanese Noonan syndrome' height provided for each sex and age. For each participant, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The scores were centered around zero. Positive SDS indicated greater height and negative SDS indicated lesser height than the mean of the reference population. The change from baseline (week 0) in the height SDS after 208 weeks of treatment was analysed. Positive value in change from baseline indicated that SDS was better than baseline SDS. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Mean · Standard deviation score
Change in Height SDS (Noonan Syndrome Reference Data in Japanese)
Standard deviation scoreNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Height SDS (Noonan Syndrome Reference Data in Japanese)0.96 ± 0.471.92 ± 0.60
SecondaryHeight Velocity

Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 156) and height at week 104 divided by time between those measurement time points and multiplied by 365 days. Missing values were imputed using the LOCF method.

Time frame:
Week 104 to week 156
Reported as:
Mean · cm/year
Height Velocity
cm/yearNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Height Velocity5.77 ± 1.267.01 ± 1.12
SecondaryHeight Velocity

Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 208) and height at week 156 divided by time between those measurement time points and multiplied by 365 days. Missing values were imputed using the LOCF method.

Time frame:
Week 156 to week 208
Reported as:
Mean · cm/year
Height Velocity
cm/yearNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Height Velocity5.64 ± 1.236.11 ± 1.28
SecondaryHeight Velocity SDS

Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 156) and height at week 104 divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using the formula: SDS = (height velocity - mean)/SD, where height velocity was the height velocity variable measured, mean and SD of height velocity by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height velocity and negative SDS indicated lesser height velocity than the mean of the reference population.

Time frame:
Week 104 to week 156
Reported as:
Mean · Standard deviation score
Height Velocity SDS
Standard deviation scoreNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Height Velocity SDS-0.39 ± 1.611.44 ± 1.25
SecondaryHeight Velocity SDS

Height velocity is change in height per year. The height velocity was calculated as the difference between current height (week 208) and height at week 156 divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using the formula: SDS = (height velocity - mean)/SD, where height velocity was the height velocity variable measured, mean and SD of height velocity by sex and age for the reference population. The scores were centered around zero. Positive SDS indicated greater height velocity and negative SDS indicated lesser height velocity than the mean of the reference population.

Time frame:
Week 156 to week 208
Reported as:
Mean · Standard deviation score
Height Velocity SDS
Standard deviation scoreNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Height Velocity SDS-0.73 ± 1.520.92 ± 1.69
SecondaryIncidence of Treatment Emergent AEs

A treatment emergent AE (TEAE) was defined as an event that had onset date on or after the date of visit 2 (week 0; start of treatment) and no later than 7 days after the last day of NN-220 treatment.

Time frame:
Week 0 to week 234 (208 weeks treatment period + 26 weeks extended treatment period) + 7 days (follow-up period)
Reported as:
Number · Events
Incidence of Treatment Emergent AEs
EventsNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Incidence of Treatment Emergent AEs507539
SecondaryChange in IGF-I

Change from baseline (within 4 weeks prior to week 0) in IGF-I was evaluated after 208 weeks of treatment. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Mean · ng/mL
Change in IGF-I
ng/mLNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in IGF-I133.5 ± 97.6217.2 ± 91.1
SecondaryChange in HbA1c

Change from baseline (within 4 weeks prior to week 0) in HbA1c was evaluated after 208 weeks of treatment.

Time frame:
Baseline, week 208
Reported as:
Mean · Percentage of HbA1c
Change in HbA1c
Percentage of HbA1cNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in HbA1c0.19 ± 0.130.20 ± 0.21
SecondaryChange in Clinical Laboratory Tests (Haematology: Erythrocytes)

Change from baseline (within 4 weeks prior to week 0) in haematological parameter - erythrocytes. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Mean · 10^12 cells/L
Change in Clinical Laboratory Tests (Haematology: Erythrocytes)
10^12 cells/LNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Haematology: Erythrocytes)0.121 ± 0.3280.095 ± 0.204
SecondaryChange in Clinical Laboratory Tests (Haematology: Leukocytes and Thrombocytes)

Change from baseline (within 4 weeks prior to week 0) in haematological parameter - leukocytes and thrombocytes. Missing values were imputed using the LOCF method.

Time frame:
Baseline, Week 208
Reported as:
Mean · 10^9 cells/L
Change in Clinical Laboratory Tests (Haematology: Leukocytes and Thrombocytes)
10^9 cells/LNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Leukocytes-1.50 ± 2.22-1.50 ± 1.57
Thrombocytes-27.5 ± 55.5-56.6 ± 58.5
SecondaryChange in Clinical Laboratory Tests (Haematology: Haemoglobin)

Change from baseline (within 4 weeks prior to week 0) in haematological parameter - haemoglobin. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Mean · mmol/L
Change in Clinical Laboratory Tests (Haematology: Haemoglobin)
mmol/LNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Haematology: Haemoglobin)0.46 ± 0.580.46 ± 0.35
SecondaryChange in Clinical Laboratory Tests (Haematology: Haematocrit)

Change from baseline (within 4 weeks prior to week 0) in haematological parameter - haematocrit. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Mean · Percentage of red blood cells
Change in Clinical Laboratory Tests (Haematology: Haematocrit)
Percentage of red blood cellsNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Haematology: Haematocrit)1.24 ± 2.451.26 ± 1.63
SecondaryChange in Clinical Laboratory Tests (Haematology: Neutrophils)

Change from baseline (within 4 weeks prior to week 0) in haematological parameter - neutrophils. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Mean · Percentage of neutrophils
Change in Clinical Laboratory Tests (Haematology: Neutrophils)
Percentage of neutrophilsNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Haematology: Neutrophils)-1.23 ± 10.804.88 ± 9.41
SecondaryChange in Clinical Laboratory Tests (Haematology: Lymphocytes)

Change from baseline (within 4 weeks prior to week 0) in haematological parameter - lymphocytes. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Mean · Percentage of lymphocytes
Change in Clinical Laboratory Tests (Haematology: Lymphocytes)
Percentage of lymphocytesNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Haematology: Lymphocytes)-0.14 ± 8.88-5.70 ± 8.86
SecondaryChange in Clinical Laboratory Tests (Haematology: Monocytes)

Change from baseline (within 4 weeks prior to week 0) in haematological parameter - monocytes. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Mean · Percentage of monocytes
Change in Clinical Laboratory Tests (Haematology: Monocytes)
Percentage of monocytesNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Haematology: Monocytes)0.08 ± 1.210.56 ± 1.18
SecondaryChange in Clinical Laboratory Tests (Haematology: Eosinophils)

Change from baseline (within 4 weeks prior to week 0) in haematological parameter - eosinophils. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Mean · Percentage of eosinophils
Change in Clinical Laboratory Tests (Haematology: Eosinophils)
Percentage of eosinophilsNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Haematology: Eosinophils)1.30 ± 3.570.42 ± 1.44
SecondaryChange in Clinical Laboratory Tests (Haematology: Basophils)

Change from baseline (within 4 weeks prior to week 0) in haematological parameter - basophils. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Mean · Percentage of basophils
Change in Clinical Laboratory Tests (Haematology: Basophils)
Percentage of basophilsNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Haematology: Basophils)-0.01 ± 0.26-0.12 ± 0.26
SecondaryChange in Clinical Laboratory Tests (Lipids: Total Cholesterol, LDL Cholesterol and HDL Cholesterol)

Change from baseline (within 4 weeks prior to week 0) in lipids: total cholesterol, LDL cholesterol and HDL cholesterol. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Mean · mmol/L
Change in Clinical Laboratory Tests (Lipids: Total Cholesterol, LDL Cholesterol and HDL Cholesterol)
mmol/LNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Total cholesterol0.031 ± 0.639-0.110 ± 0.609
LDL cholesterol-0.005 ± 0.550-0.173 ± 0.523
HDL cholesterol0.036 ± 0.2750.056 ± 0.173
SecondaryChange in Clinical Laboratory Tests (Biochemistry: AST, ALT, r-GTP and Alkaline Phosphatase)

Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - AST, ALT, r-GTP and alkaline phosphatase. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Mean · U/L
Change in Clinical Laboratory Tests (Biochemistry: AST, ALT, r-GTP and Alkaline Phosphatase)
U/LNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
AST-5.4 ± 2.4-7.4 ± 5.2
ALT-1.28 ± 2.65-1.81 ± 4.42
r-GTP1.0 ± 1.6-3.5 ± 22.8
Alkaline phosphatase113.9 ± 126.484.8 ± 140.9
SecondaryChange in Clinical Laboratory Tests (Biochemistry: Total Protein)

Change from baseline (within 4 weeks prior to week 0) in biochemical parameter - total protein. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Mean · g/dL
Change in Clinical Laboratory Tests (Biochemistry: Total Protein)
g/dLNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Biochemistry: Total Protein)0.02 ± 0.330.05 ± 0.37
SecondaryChange in Clinical Laboratory Tests (Biochemistry: Blood Urea Nitrogen, Sodium, Potassium, Chloride, Total Calcium and Phosphorus)

Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - blood urea nitrogen, sodium, potassium, chloride, total calcium and phosphorus. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Mean · mmol/L
Change in Clinical Laboratory Tests (Biochemistry: Blood Urea Nitrogen, Sodium, Potassium, Chloride, Total Calcium and Phosphorus)
mmol/LNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Blood urea nitrogen-0.10 ± 0.52-0.15 ± 0.53
Sodium0.9 ± 2.11.4 ± 2.5
Potassium-0.13 ± 0.28-0.09 ± 0.38
Chloride-0.3 ± 2.2-0.2 ± 2.2
Total calcium-0.02 ± 0.07-0.00 ± 0.08
Phosphorus0.036 ± 0.1110.111 ± 0.103
SecondaryChange in Clinical Laboratory Tests (Biochemistry: Creatinine)

Change from baseline (within 4 weeks prior to week 0) in biochemical parameters - creatinine. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Mean · umol/L
Change in Clinical Laboratory Tests (Biochemistry: Creatinine)
umol/LNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Clinical Laboratory Tests (Biochemistry: Creatinine)5.5 ± 4.46.7 ± 4.1
SecondaryChange in Glucose Tolerance (AUC of Glucose) Based on the OGTT

AUC of glucose was calculated by the trapezoidal method. Change from baseline (within 4 weeks prior to week 0) in glucose tolerance (AUC of glucose: 30, 60, 90 and 120 min after oral glucose load) at week 208 was evaluated based on the OGTT. Change from baseline results are presented as 'ratio to baseline'.

Time frame:
Baseline, week 208
Reported as:
Geometric mean · Ratio of AUC
Change in Glucose Tolerance (AUC of Glucose) Based on the OGTT
Ratio of AUCNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Glucose Tolerance (AUC of Glucose) Based on the OGTT1.03 ± 12.341.10 ± 14.55
SecondaryChange in Glucose Tolerance (AUC of Insulin) Based on the OGTT

AUC of insulin was calculated by the trapezoidal method. Change from baseline (within 4 weeks prior to week 0) in glucose tolerance (AUC of insulin: 30, 60, 90 and 120 min after oral glucose load) at week 208 was evaluated based on the OGTT. Change from baseline results are presented as 'ratio to baseline'.

Time frame:
Baseline, week 208
Reported as:
Geometric mean · Ratio of AUC
Change in Glucose Tolerance (AUC of Insulin) Based on the OGTT
Ratio of AUCNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Glucose Tolerance (AUC of Insulin) Based on the OGTT1.52 ± 49.972.38 ± 47.04
SecondaryChange in Bone Age

X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Change from baseline (week 0) in bone age.

Time frame:
Baseline, week 208
Reported as:
Mean · Years
Change in Bone Age
YearsNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Bone Age3.89 ± 1.354.68 ± 1.11
SecondaryChange in Bone Age/Chronological Age

X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Change from baseline (week 0) in bone age/chronological age.

Time frame:
Baseline, week 208
Reported as:
Mean · Ratio (bone age/chronological age)
Change in Bone Age/Chronological Age
Ratio (bone age/chronological age)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Bone Age/Chronological Age0.049 ± 0.1590.149 ± 0.151
SecondaryYearly Change in Bone Age/Change in Chronological Age

X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Yearly change from week 104 in bone age/change in chronological age was presented.

Time frame:
Week 104, week 156
Reported as:
Mean · Ratio (bone age/chronological age)
Yearly Change in Bone Age/Change in Chronological Age
Ratio (bone age/chronological age)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Yearly Change in Bone Age/Change in Chronological Age0.94 ± 0.700.97 ± 0.56
SecondaryYearly Change in Bone Age/Change in Chronological Age

X-ray picture of carpal bones of left hand was taken for bone age determination. Centralised evaluation of bone age was done by the RUS score method of Tanner-Whitehouse II (TW2). Yearly change from week 156 in bone age/change in chronological age was presented.

Time frame:
Week 156, week 208
Reported as:
Mean · Ratio (bone age/chronological age)
Yearly Change in Bone Age/Change in Chronological Age
Ratio (bone age/chronological age)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Yearly Change in Bone Age/Change in Chronological Age0.87 ± 0.551.05 ± 0.51
SecondaryChange in Vital Signs (Diastolic Blood Pressure and Systolic Blood Pressure)

Systolic and diastolic blood pressure were measured after a 5-minute rest in sitting position. Change from baseline (week 0) in systolic blood pressure and diastolic blood pressure. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Mean · mmHg
Change in Vital Signs (Diastolic Blood Pressure and Systolic Blood Pressure)
mmHgNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Diastolic blood pressure5.8 ± 13.43.5 ± 8.4
Systolic blood pressure6.8 ± 11.95.8 ± 16.1
SecondaryChange in Vital Signs (Pulse)

Pulse was measured after a 5-minute rest in sitting position. Change from baseline (week 0) in pulse. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Mean · beats/min
Change in Vital Signs (Pulse)
beats/minNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Change in Vital Signs (Pulse)-15.3 ± 14.2-3.8 ± 16.5
SecondaryChange in Urinalysis (Protein, Glucose and Occult Blood)

The urinalysis was the measurements of protein, glucose, and occult blood at baseline (within 4 weeks prior to week 0) and week 208 and categorised as negative, trace, 1+, 2+ and 3+. Number of participants in each category at baseline and week 208 are presented. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Count of participants · Participants
Change in Urinalysis (Protein, Glucose and Occult Blood)
ParticipantsNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Protein: Negative (Baseline)2322
Protein: Trace (Baseline)24
Protein: 1+ (Baseline)00
Protein: 2+ (Baseline)00
Protein: 3+ (Baseline)00
Protein: Negative (Week 208)1718
Protein: Trace (Week 208)87
Protein: 1+ (Week 208)00
Protein: 2+ (Week 208)01
Protein: 3+ (Week 208)00
Glucose: Negative (Baseline)2526
Glucose: Trace (Baseline)00
Glucose: 1+ (Baseline)00
Glucose: 2+ (Baseline)00
Glucose: 3+ (Baseline)00
Glucose: Negative (Week 208)2526
Glucose: Trace (Week 208)00
Glucose: 1+ (Week 208)00
Glucose: 2+ (Week 208)00
Glucose: 3+ (Week 208)00
Occult blood: Negative (Baseline)2425
Occult blood: Trace (Baseline)11
Occult blood: 1+ (Baseline)00
Occult blood: 2+ (Baseline)00
Occult blood: 3+ (Baseline)00
Occult blood: Negative (Week 208)2422
Occult blood: Trace (Week 208)12
Occult blood: 1+ (Week 208)01
Occult blood: 2+ (Week 208)00
Occult blood: 3+ (Week 208)01
SecondaryChange in Blood Coagulation Test (Prothrombin Time and APTT)

Change from baseline (within 4 weeks prior to week 0) in blood coagulation test parameters: prothrombin time and APTT. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Median · sec
Change in Blood Coagulation Test (Prothrombin Time and APTT)
secNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Prothrombin time0.70 (-0.3 to 2.4)1.20 (-0.2 to 2.2)
APTT0.70 (-5.3 to 5.0)0.80 (-7.4 to 6.4)
SecondaryChange in ECG

The ECG was recorded after a 3-minute rest in supine position at baseline (within 4 weeks prior to week 0) and week 208 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline and week 208 are presented. Missing values were imputed using the LOCF method.

Time frame:
Baseline, week 208
Reported as:
Count of participants · Participants
Change in ECG
ParticipantsNN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/Day
Normal (Baseline)1514
Abnormal NCS (Baseline)1012
Abnormal CS (Baseline)00
Normal (Week 208)2016
Abnormal NCS (Week 208)59
Abnormal CS (Week 208)01

Adverse events

Collected over Week 0 to week 234 (208 weeks treatment period + 26 weeks extended treatment period) + 7 days (follow-up period).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.033 mg/kg/Day0/25 (0%)9/25 (36%)24/25 (96%)
0.066 mg/kg/Day0/26 (0%)10/26 (38.5%)26/26 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
Event0.033 mg/kg/Day0.066 mg/kg/Day
Dental cariesGastrointestinal disorders2/250/26
Arnold-Chiari malformationCongenital, familial and genetic disorders1/250/26
CraniosynostosisCongenital, familial and genetic disorders1/251/26
HamartomaCongenital, familial and genetic disorders1/250/26
Head bangingPsychiatric disorders1/250/26
PhimosisCongenital, familial and genetic disorders1/250/26
PneumoniaInfections and infestations1/250/26
Pneumonia mycoplasmalInfections and infestations1/251/26
Salivary gland calculusGastrointestinal disorders1/250/26
Atrial fibrillationCardiac disorders0/251/26
Most frequent other events
Showing 10 of 55
Most frequent other events
Event0.033 mg/kg/Day0.066 mg/kg/Day
NasopharyngitisInfections and infestations19/2521/26
InfluenzaInfections and infestations20/2518/26
GastroenteritisInfections and infestations8/2514/26
PyrexiaGeneral disorders9/259/26
Upper respiratory tract infectionInfections and infestations8/259/26
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders7/259/26
EczemaSkin and subcutaneous tissue disorders3/258/26
Otitis mediaInfections and infestations7/258/26
DiarrhoeaGastrointestinal disorders7/253/26
BronchitisInfections and infestations4/257/26

Baseline characteristics

Full analysis set (FAS) which included all randomised participants.

Age, Continuous
Age, Continuous(years)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/DayTotal
Mean6.57 ± 2.426.06 ± 2.256.31 ± 2.32
Sex: Female, Male
Sex: Female, Male(Participants)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/DayTotal
Female11819
Male141832
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/DayTotal
American Indian or Alaska Native000
Asian252651
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/DayTotal
Count of participants——0
Height standard deviation score (SDS) (Japanese national reference data)
Height standard deviation score (SDS) (Japanese national reference data)(Standard deviation score)NN-220 0.033 mg/kg/DayNN-220 0.066 mg/kg/DayTotal
Mean-3.24 ± 0.76-3.25 ± 0.71-3.24 ± 0.73
08

Study locations

27 sites
  • Novo Nordisk Investigational Site
    Asahikawa, Hokkaido, 078-8510, Japan
  • Novo Nordisk Investigational Site
    Fukuoka, 812-8582, Japan
  • Novo Nordisk Investigational Site
    Fukuoka, 830-0011, Japan
  • Novo Nordisk Investigational Site
    Iruma-gun, Saitama, 350 0495, Japan
  • Novo Nordisk Investigational Site
    Kanagawa, 216-8511, Japan
  • Novo Nordisk Investigational Site
    Kanagawa, 232-8555, Japan
  • Novo Nordisk Investigational Site
    Kyoto, 602-8566, Japan
  • Novo Nordisk Investigational Site
    Maebashi-shi, Gunma, 371-8511, Japan
  • Novo Nordisk Investigational Site
    Miyazaki, 889-1692, Japan
  • Novo Nordisk Investigational Site
    Nagoya, Aichi, 467-8602, Japan
  • Novo Nordisk Investigational Site
    Niigata-shi, Niigata, 951 8520, Japan
  • Novo Nordisk Investigational Site
    Oita, 879-5593, Japan
  • Novo Nordisk Investigational Site
    Osaka, 534-0021, Japan
  • Novo Nordisk Investigational Site
    Osaka, 594-1101, Japan
  • Novo Nordisk Investigational Site
    Saitama-city, Saitama, 336-8522, Japan
  • Novo Nordisk Investigational Site
    Saitama-shi, Saitama, 330-8777, Japan
  • Novo Nordisk Investigational Site
    Sapporo, Hokkaido, 065-8611, Japan
  • Novo Nordisk Investigational Site
    Sendai-shi, Miyagi, 980 8574, Japan
  • Novo Nordisk Investigational Site
    Shizuoka, 431-3192, Japan
  • Novo Nordisk Investigational Site
    Tochigi, 329-0498, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 113-8519, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 113-8655, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 157 8535, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 160-8582, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 162-8666, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 183-8561, Japan
  • Novo Nordisk Investigational Site
    Zentsuji, Kagawa, 765-8507, Japan
09

References and documents

Publications

  • Horikawa R, Ogata T, Matsubara Y, Yokoya S, Ogawa Y, Nishijima K, Endo T, Ozono K. Long-term efficacy and safety of two doses of Norditropin(R) (somatropin) in Noonan syndrome: a 4-year randomized, double-blind, multicenter trial in Japanese patients. Endocr J. 2020 Aug 28;67(8):803-818. doi: 10.1507/endocrj.EJ19-0371. Epub 2020 May 9. PubMed 32269181 ↗
  • Ozono K, Ogata T, Horikawa R, Matsubara Y, Ogawa Y, Nishijima K, Yokoya S. Efficacy and safety of two doses of Norditropin(R) (somatropin) in short stature due to Noonan syndrome: a 2-year randomized, double-blind, multicenter trial in Japanese patients. Endocr J. 2018 Feb 26;65(2):159-174. doi: 10.1507/endocrj.EJ17-0313. Epub 2017 Nov 7. PubMed 29109363 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2013 to primary completion in Jul 2018, 58 months.

Results were first posted in Oct 2019, 1 year 3 months after primary completion.

Of 39 industry-sponsored phase 3 interventional studies under Genetic Diseases, Inborn, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's 58 months is above that.

Counting every sponsor, half of 40 studies reached it within 34 months; a quarter within 24 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2013
First posted
Aug 23, 2013
StartActual
Aug 19, 2013
Primary completionActual
Jul 12, 2018
CompletionActual
Jul 12, 2018
Results first posted
Oct 14, 2019
Last update
Aug 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01927861
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 23, 2013
Start date
Aug 19, 2013
Primary completion
Jul 12, 2018
Completion
Jul 12, 2018
Results posted
Oct 14, 2019
Last update
Aug 10, 2020

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion